Daily non-political popular news in brief.

Half of patients with active early rheumatoid arthritis achieved clinical remission

11-07-2007 · EurekAlert!

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced that data from a multicenter, randomized, double-blind trial of ENBREL plus methotrexate showed that 50 percent of patients with active early rheumatoid arthritis achieved clinical remission at one year.

Keywords: half, patients, active, rheumatoid, arthritis, achieved, clinical, remission, patient, arthriti

« Previous | Next »

Similar news on "Half of patients with active early rheumatoid arthritis achieved clinical remission":

First multinational study of Tocilizumab reports in
06-15-2007 · EurekAlert!
Nearly half -- 43.9 percent -- of rheumatoid arthritis patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50 percent improvement in symptoms at 24 weeks and more than one fifth achieved a 70 percent symptom improvement, according to results of a European study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. This study is the first phase III trial of tocilizumab.
Similar news · Read more »
Latest data shows MabThera provides significant, sustained relief from symptoms of RA
06-13-2007 · EurekAlert!
New data presented at the EULAR meeting demonstrate that MabThera's effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.
Similar news · Read more »
Patient choice and treatment alternatives for arthritis
06-28-2007 · EurekAlert!
Two new studies examined patients' decisions regarding therapy for RA and glucosamine for OA and found that most RA patients are reluctant to change their treatment as long as their condition didn't worsen, and that there are discrepancies in clinical trial results for glucosamine.
Similar news · Read more »
Annals of Internal Medicine tip sheet for March 20, 2007
03-19-2007 · EurekAlert!
The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
Similar news · Read more »
Rheumatoid arthritis sends many into early retirement
02-04-2008 · EurekAlert!
A joint study on "The Burden of Rheumatoid Arthritis and Patient Access to Treatments" by authors from the Stockholm School of Economics, the University of Lund and the Medical University of Vienna has shown that the highest cost in rheumatoid arthritis results from patients having to leave the workforce early due to the disease. The study has just been published online in a supplement to Springer's The European Journal of Health Economics.
Similar news · Read more »
One-fifth of patients in drug-free remission following early treatment with Infliximab and Methotrex
06-14-2007 · EurekAlert!
Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Similar news · Read more »
HGS announces positive Phase 2 LymphoStat-B at ACR meeting
11-09-2007 · EurekAlert!
Human Genome Sciences, Inc. today announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus.
Similar news · Read more »
Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
12-20-2007 · EurekAlert!
The largest study to examine the effect of depression on HIV treatment appears in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The study by Kaiser Permanente and Group Health found depression significantly worsens a patient's adherence to highly active antiretroviral therapy and clinical measures but that effective antidepressant medication reverses this outcome. The study looked at 3,359 HIV-infected patients to measure the effects of depression -- with and without SSRIs.
Similar news · Read more »
Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
10-23-2006 · EurekAlert!
Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
Similar news · Read more »
1/5 of patients in drug-free remission following early treatment with Infliximab and Methotrex
06-14-2007 · EurekAlert!
Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Similar news · Read more »